Nektar Therapeutics (NKTR) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 --0%
EPS Growth %: -215.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Exelon (EXC) PT Lowered to $49 at Argus
- UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
